"This variant plays essentially no role in whether an individual initiates smoking or not, which is strongly driven by environmental factors. However, if a person with the high-risk does begin smoking, they will smoke a higher number of s per day, have a higher intensity of smoking, and have a higher age of smoking cessation than those with the low-risk variant, increasing their risk for . The problem with smoking cessation pharmacotherapy using is that it works modestly, at best, and the vast majority of smoking cessation is done without any medication. However, data suggest that people with the high-risk variant rs16969968 have the greatest difficulty quitting and stand to benefit the most from medication, although the evidence is still controversial. This makes sense since this variant affects function. Improved implementation of pharmacotherapy, using patients’ genetics as a guide, could have a huge impact."

"Smoking increases mortality from all causes and has a crucial role in . Active smoking and exposure determine more than 30% of mortality. The exact mechanisms of cardiovascular damages are not well known, but the detrimental effect of smoking on endothelial function has long been recognized. Smoking elicits oxidative processes, negatively affects platelet function, , inflammation and vasomotor function; all these proatherogenic effects double the 10-year risk of fatal events in smokers compared to non smokers. An intriguing issue about smoking is the vulnerability of female gender. The mortality from cardiovascular diseases (CVDs) is higher in female than male smokers and female smokers show a 25% higher risk of developing CHD than men with the same exposure to tobacco smoke. This female vulnerability seems to be related to genes involved in thrombin signaling. The effects of smoking cessation have also been extensively studied. Cessation at an early age (40 years) has an impressive 90% reduction in the excess risk of death."

"There is high‐certainty evidence that can aid long‐term smoking cessation. However, bupropion also increases the number of adverse events, including psychiatric , and there is high‐certainty evidence that people taking bupropion are more likely to discontinue treatment compared with placebo. However, there is no clear evidence to suggest whether people taking bupropion experience more or fewer than those taking placebo (moderate certainty). also appears to have a beneficial effect on smoking quit rates relative to placebo. Evidence suggests that bupropion may be as successful as and nortriptyline in helping people to quit smoking, but that it is less effective than varenicline. There is insufficient evidence to determine whether the other antidepressants tested, such as s, aid smoking cessation, and when looking at safety and tolerance outcomes, in most cases, paucity of data made it difficult to draw conclusions."

"Cigarette smoking is the primary cause of , and smoking cessation is the most effective means of stopping the progression of chronic obstructive pulmonary disease. Worldwide, approximately a billion people smoke cigarettes and 80% reside in low-income and middle-income countries. Though in the United States there has been a substantial decline in cigarette smoking since 1964, when the Surgeon General's report first reviewed smoking, smoking remains widespread in the United States today (about 23% of the population in 2001). Nicotine is addictive, but there are now effective drugs and behavioral interventions to assist people to overcome the addiction. Available evidence shows that smoking cessation can be helped with counseling, nicotine replacement, and bupropion. Less-studied interventions, including hypnosis, acupuncture, aversive therapy, exercise, , s, , s, and , have assisted some people in smoking cessation, but none of those interventions has strong research evidence of efficacy. To promote smoking cessation, physicians should discuss with their smoking patients “relevance, risk, rewards, roadblocks, and repetition,” and with patients who are willing to attempt to quit, physicians should use the 5-step system of “ask, advise, assess, assist, and arrange.”"

"If I mention , I am sure most people in this room understandably think of cocaine — but freebasing was invented by the . You add and to the tobacco leaf mixture — the smoke that's produced is more basic, more alkaline. And, as a consequence, nicotine is delivered across the {[w|Pulmonary alveolus|alveolar membrane}} even more rapidly than would otherwise be the case. And we know that the rapidity — with which a drug is delivered and sating a need for a drug — is an important determinant of its propensity to induce and maintain addiction, et cetera, et cetera, et cetera. And we could take the entire hour talking about the elements of cigarette design. … It is important that we understand that we have the most addictive substance in our community — whose use is facilitated by a perversely engineered drug delivery device."

"’s (AC) method is a pharmacotherapy-free approach to quit smoking that is delivered through seminars, online courses, or in the form of a book. It has gained popularity, but its effectiveness remains controversial due to a lack of scientific evidence."